AiCure

WuXi PharmaTech

WuXi PharmaTech acquires XenoBiotic Laboratories

Wednesday, October 1, 2014 01:11 PM

CRO WuXi PharmaTech, with operations in China and the U.S., has acquired XenoBiotic Laboratories (XBL), a CRO with facilities in New Jersey and China. Financial terms have not been disclosed.

More... »


FDA approves WuXi’s manufacture of ibalizumab in China for use under a U.S. IND

Wednesday, May 7, 2014 01:32 PM

The FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product, manufactured at WuXi PharmaTech's biologics facilities and developed by TaiMed Biologics for the treatment of HIV/AIDS infection. 

More... »


WuXi PharmaTech invests in TruTag security platform for drug safety

Monday, April 7, 2014 12:36 PM

CRO WuXi PharmaTech, with operations in China and the U.S., and TruTag Technologies, developer of an edible, covert security platform to address the global product counterfeiting challenge, have announced that WuXi Corporate Venture Fund has made an investment in TruTag.

More... »

WuXi PharmaTech, Pharmacyclics to partner

Monday, November 18, 2013 01:48 PM

CRO WuXi PharmaTech, with operations in China and the U.S., said its subsidiary Shanghai SynTheAll (STA) Pharmaceutical has entered into a supply arrangement with Pharmacyclics. This follows a successful multiple-year development and clinical manufacturing partnership that supported Pharmacyclics with an expedited NDA submission and final approval by the FDA of Imbruvica  on Nov. 13, for treatment of patients with mantle cell lymphoma who have received at least one prior therapy.  This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established. 

More... »

WuXi’s genomics clinical laboratory receives CLIA certification

Monday, October 21, 2013 01:32 PM

CRO WuXi PharmaTech, with operations in China and the U.S., said its genomics clinical laboratory in Shanghai has successfully passed the survey by the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services relating to CLIA (Clinical Laboratory Improvement Amendments) standards, thereby receiving CLIA certification. WuXi's laboratory is the only CLIA-certified clinical laboratory in China.

More... »

The CenterWatch Monthly, August 2013

Friday, August 2, 2013 10:36 AM

Will end-to-end outsourcing take hold?

More... »

Ambrx, Zhejiang Medicine, WuXi PharmaTech collaborate

Tuesday, June 18, 2013 09:32 AM

Ambrx, a clinical stage biopharmaceutical company, and China-based pharmaceutical Zhejiang Medicine (ZMC) are collaborating to develop and commercialize ARX788, Ambrx’s internally developed, site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

More... »

WuXi PharmaTech, PRA form joint venture for Chinese market

Thursday, December 20, 2012 10:32 AM

CRO WuXi PharmaTech, with operations in China and the U.S., and CRO PRA have signed a joint venture agreement to offer a broad platform of phase I-IV clinical trial services in China, Hong Kong and Macau, including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting and medical monitoring.

More... »

Drug discovery services market to reach $16.6B in 2015

Monday, December 10, 2012 10:09 AM

A new report by visiongain, an independent media company based in London, predicts that the world market for drug discovery outsourcing will reach $16.6 billion in 2015. That revenue forecast and others appear in “DrugDiscovery Outsourcing: World Market 2013-2023,” published in November 2012.

More... »

WuXi AppTec opens first cGMP biologics facility in China

Monday, October 22, 2012 11:11 AM

WuXi AppTec, a pharmaceutical, biotechnology and medical device R&D outsourcing company, has opened a cGMP biologics facility in China.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs